Arvinas Inc ARVN

$6.82 -0.05 (-0.73%)

Valuation

Market cap
449,882,000
Revenue TTM
$262,600,000
Net income TTM
$-80,800,000
P/E (trailing)
0.00
P/E (forward)
26.08
Profit margin
-30.77%
Debt to equity
0.00

Trading

Volume
879,300
Avg volume
870,766
Day's range
$6.61 – $6.90
Shares out
65,485,000
Stochastic %K
35%
Beta
1.81
Analysts
Moderate Buy
Price target
$14.14

Price

Company profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development...

Show more

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Industry
Biotechnology
Sector
Healthcare
Phone
203 535 1456
Website
https://www.arvinas.com
Address
5 Science Park, 395 Winchester Avenue, New Haven, United States

Latest news

Stocktwits

Massimo21 Nov 13, 6:48 PM
$ARVN ARV-806 presentations at 38th EORTC–NCI–AACR Symposium, 18–20 November 2026 Oral 7: ARV-806, a PROTAC KRAS G12D Degrader, in Patients With KRAS G12D–Mutated Advanced Solid Tumors: Preliminary Phase 1 Results Posters 289: Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Chemotherapy in KRAS G12D–Mutated Pancreatic Cancer Models 290: Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models 291: Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With the RAS-ON Multi-Selective Inhibitor Daraxonrasib in KRAS G12D–Mutated Models
0 replies
Regulator06 Nov 12, 2:55 PM
$ARVN Added! Can’t go wrong with the first company to be approved for PROTAC degrader. Glta!
0 replies
buyandsold Nov 6, 6:52 PM
$ARVN what a bounce. Degrader pioneer!
0 replies
NewGuyHere94 Nov 6, 3:43 PM
$ARVN data in December, an Xmas present hopefully
0 replies
BullDonald Nov 5, 8:20 PM
$ARVN Wont hide.... M scared Dawg.... this Sucks. My whole Portfolio Sucks.
0 replies
NewGuyHere94 Nov 5, 7:03 PM
$ARVN essentially a reset of where this stock was april 2025, back on the train to the next phases.
0 replies
oaksapollo Nov 4, 9:06 PM
$ARVN Not sure why they didn't put any of the data in the press release, but here is the full abstract.
1 replies
Massimo21 Nov 4, 2:31 PM
$ARVN From ASH 2026 abstract, "ARV-393, an oral PROTAC BCL6 degrader, in patients with non-Hodgkin lymphoma: Preliminary results from a phase 1 study". Preliminary PK demonstrated dose-dependent increases in ARV-393 exposure, with steady-state trough concentrations below the predicted efficacious exposure range for DLBCL and approaching the lower bound at 35 mg QD. Preliminary antitumor activity, including complete responses (CRs), was observed in evaluable pts with B-cell NHL (including FL and large B-cell lymphoma) and T-cell lymphomas treated at dose levels up to 35 mg QD, with dose escalation ongoing. Among 9 evaluable pts with nTFHL-AI, objective responses were observed in 4, including 3 CRs. Evidence of BCL6 degradation was observed in PBMCs and across B- and T-cell tumors.
1 replies